Skip to content
All peptides
Gastric pentadecapeptide

BPC-157

Also known as: Body Protection Compound, Pentadecapeptide BPC 157

Tier 3 — Animal / in vitroReviewed 2026-04-30

Extensively studied in rodents for tissue healing. Human evidence is essentially absent — community framing far outpaces the data.

Ask about BPC-157

Answers are grounded in the literature ingested for this peptide. Every clinical claim cites a source. Out-of-scope questions (pediatric dosing, pregnancy, oncology, personal medical advice) will be refused. Beta — verify everything important with your clinician.

Examples: “What dose was used in the SURMOUNT-1 trial?” · “Are there any cardiovascular outcome data?”

Overview

BPC-157 is a synthetic 15-amino-acid sequence first isolated by the Sikiric group in Croatia and characterized in rodent models of inflammation and tissue injury. The preclinical literature is large and consistent across tendon, gut, vascular, and central nervous system injury models. Human evidence is limited to small case series and a handful of mechanistic measurements; there are no published Phase 2 or Phase 3 RCTs in humans for any musculoskeletal or gastrointestinal indication.

Mechanism

Mechanisms documented in animals include upregulation of VEGF and growth-factor signaling at injury sites, modulation of nitric oxide pathways, dopaminergic and serotonergic effects in the CNS, and gut–brain axis activity. The translation of these mechanisms to clinical effect in humans is not established.

Evidence by indication

We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.

Tendon and ligament healing

Tier 3high confidence

Multiple rat studies show accelerated tendon-to-bone healing and ligament recovery. No published human RCTs for musculoskeletal indications. One small uncontrolled human case series in athletes with self-reported outcomes.

Sikiric P et al. 2018Sikiric P et al. 2022

Gastrointestinal inflammation (IBD-adjacent)

Tier 3high confidence

Rodent colitis models show consistent mucosal healing. One small uncontrolled human case series reports symptom improvements at ~2 weeks. No RCTs.

Sikiric P et al. 2022

Neuroprotection / CNS recovery

Tier 3high confidence

Animal models of stroke, traumatic brain injury, and neuroleptic-induced dyskinesia show protective effects. No human evidence.

Sikiric P et al. 2022

Joint pain / osteoarthritis

Tier 4medium confidence

No RCTs and no published animal models with direct OA endpoints. Online discussion is heavy; primary literature is sparse for this specific indication.

No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.

Studied dose ranges

The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.

250–500 mcg1–2× daily · subcutaneous near injury site or systemic

These ranges reflect self-experimenter community consensus extrapolated from animal dose-equivalence calculations, not human dose-finding studies. Treat as approximate.

Contraindications

  • Active malignancy (theoretical concern given growth-factor upregulation in animal models)
  • Pregnancy and breastfeeding (no human safety data)
  • Hypersensitivity to peptide excipients
  • Long-term continuous use beyond ~30 days lacks human safety data

Reported side effects

  • Injection site reactions
  • Mild fatigue or sedation reported anecdotally
  • Headache
  • GI upset with oral administration
  • No long-term human safety data — flag explicitly

Reconstitution & storage

Lyophilized powder reconstituted with bacteriostatic water. A 5 mg vial in 2.5 mL BAC water = 2 mg/mL, making a 250 mcg dose ~12.5 units on a U-100 syringe. Use the calculator to verify.

Storage. Lyophilized: room temperature acceptable short-term; refrigeration extends stability. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.

Editorial note

BPC-157 is the most over-claimed peptide in self-experimenter communities. Hold the line at Tier 3 for every indication. Do not be moved by anecdote; do not be moved by mechanism alone. The Sikiric corpus is impressive in scope but is almost entirely from a single research group, which is a methodological caution flag in itself.

Citations

  1. [1]
    Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease and other indications — Mediator of Wnt/β-catenin pathway
    Sikiric P, Hahm KB, Blagaic AB, et al. · Current Pharmaceutical Design · 2018 · PMID 29186999
    Mechanistic and tissue-healing animal evidence used as a Tier 3 anchor.
    View source
  2. [2]
    Stable Gastric Pentadecapeptide BPC 157: Therapeutic Effect in the Cardiovascular System
    Sikiric P, Drmic D, Sever M, et al. · Frontiers in Pharmacology · 2022 · PMID 30821044
    Cross-system review used to anchor multiple Tier 3 indications.
    View source